secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001493152-26-001004
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics appoints David Natan to board and audit committee
-----------------------------------------------------------------------

- Board increased from 8 to 9 members; David Natan appointed as Class II director until 2026 annual meeting.
- Natan replaces Avraham Ben-Tzvi as Audit Committee member; Ben-Tzvi to become paid consultant while remaining on board.
- Natan was designated by David E. Lazar under securities purchase agreement dated December 22, 2025.
- Natan is CPA and CEO of Natan & Associates; also serves on boards of Sunshine Biopharma and FIEE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226001004/0001493152-26-001004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226001004/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-001004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer